« New SAFC Corporate Video | Main | Health Care Reform - Half a Loaf? »

03/23/2010

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a0120a77f675b970b01310fd05d95970c

Listed below are links to weblogs that reference Compelled to Give a Positive Note on NSCLC :

Comments

Feed You can follow this conversation by subscribing to the comment feed for this post.

bigredbruce

BMS announced more good news from mid-stage study with ipilimumab with positive stock results to boot
http://seekingalpha.com/article/206783-bristol-meyers-squibb-encouraging-cancer-drug-data

Bruce Lehr

Once again I see another instance in news this morning (March 29th) of a failure in clinicals for a NSCLC therapy. This time we're talking about Antisoma's trial biting the dust and its subsequent 72% drop in market value as a result. See the pharmaletter ( http://bit.ly/bhG5pG ) and In the Pipeline (http://seekingalpha.com/article/196079-antisoma-s-phase-iii-disaster) for more information.

Bruce Lehr

No sooner do I make a positive post on treatment of NSCLC than I see another potential downer. EMD Merck just suspended trials on its Stimulvax (BLP25 liposome vaccine) due to a severe adverse effect in a patient with multiple myeloma.

However, the suspension also affects patient recruitment in two other Phase III trials (START & INSPIRE) Merck is running for NSCLC.

http://bit.ly/c7I7Li

The comments to this entry are closed.

My Photo
Blog powered by Typepad
Member since 12/2009
Bookmark and Share

April 2014

Sun Mon Tue Wed Thu Fri Sat
    1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30      

Innovate on Purpose

In the Pipeline

Life Sci VC


visited 6 states (46.1%)
Create your own visited map of Canada